Add to ORKGIn the given article, the authors discuss the most difficult issue of the pediatrics, which is the treatment of the severe bronchial asthma. Our columnist is professor A.S. Kolbin introduces omalizumab, a new medication from the monoclonal antibodies group, to our readers. It allows practitioners to control the severe persistent bronchial asthma. The article accentuates the clinical effectiveness and pharmacoeconomic aspects of the medication application.Key words: bronchial asthma, severe run, treatment, monoclonal antibodies, children
Omalizumab, a humanized monoclonal antibody that binds circulating IgE antibody, is a treatment opti...
The monoclonal antibodies, especially omalizumab, are new drugs that are showing great efficacy in t...
Bronchial asthma is a widespread disease of the respiratory system, has a significant impact on the ...
In the given article, the authors discuss the most difficult issue of the pediatrics, which is the t...
Antibodies to IgE are a totally new class of medications currently used to enhance the supervision o...
Omalizumab, a medicine of the recombinant humanized mono clonal antibodies to Ige, is applied in rus...
The article describes a modern approach to the use of anti-IgE therapy for allergic bronchial asthma...
The article summarizes a two-year experience of treating children and adolescents with severe uncont...
IF 2.598International audienceOmalizumab is a subcutaneously administrated monoclonal anti-IgE antib...
Omalizumab, whose active basis is recombinant, human, monoclonal antibodies to Ige, gives a unique t...
<em>The review of safety of monoclonal anti-ige-antibodies (xolair) — a new medication for the treat...
Over 300 million people worldwide suffer from asthma, a chronic respiratory condition characterised ...
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiven...
The article presents a generalized 2-year Russian experience in the application of monoclonal antibo...
This article studies the specifics of allergic diseases pathogenesis. Such common allergic diseases ...
Omalizumab, a humanized monoclonal antibody that binds circulating IgE antibody, is a treatment opti...
The monoclonal antibodies, especially omalizumab, are new drugs that are showing great efficacy in t...
Bronchial asthma is a widespread disease of the respiratory system, has a significant impact on the ...
In the given article, the authors discuss the most difficult issue of the pediatrics, which is the t...
Antibodies to IgE are a totally new class of medications currently used to enhance the supervision o...
Omalizumab, a medicine of the recombinant humanized mono clonal antibodies to Ige, is applied in rus...
The article describes a modern approach to the use of anti-IgE therapy for allergic bronchial asthma...
The article summarizes a two-year experience of treating children and adolescents with severe uncont...
IF 2.598International audienceOmalizumab is a subcutaneously administrated monoclonal anti-IgE antib...
Omalizumab, whose active basis is recombinant, human, monoclonal antibodies to Ige, gives a unique t...
<em>The review of safety of monoclonal anti-ige-antibodies (xolair) — a new medication for the treat...
Over 300 million people worldwide suffer from asthma, a chronic respiratory condition characterised ...
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiven...
The article presents a generalized 2-year Russian experience in the application of monoclonal antibo...
This article studies the specifics of allergic diseases pathogenesis. Such common allergic diseases ...
Omalizumab, a humanized monoclonal antibody that binds circulating IgE antibody, is a treatment opti...
The monoclonal antibodies, especially omalizumab, are new drugs that are showing great efficacy in t...
Bronchial asthma is a widespread disease of the respiratory system, has a significant impact on the ...